Knowing that biotechnology stocks and exchange-traded funds are struggling to start, that headline gives away the fact the ETF that is on a blistering pace is an inverse fund.
With the biotech sector's well-known penchant for volatility on the way down, an ETF such as the Direxion Daily S&P Biotech Bear 3X Shares (NYSE: LABD) can prove particularly rewarding in the current environment. LABD is up about 27 percent month-to-date, making it the third-best performer in Direxion's stable of bearish leveraged ETFs.
But wait. There's more. Year-to-date, LABD has nearly tripled. By comparison, the SPDR S&P Biotech (ETF) (NYSE: ...
/www.benzinga.com/general/biotech/16/02/6246548/this-biotech-etf-is-setting-a-blistering-pace alt=This Biotech ETF Is Setting A Blistering Pace>Full story available on Benzinga.com
More...